Drugs / Human (allogeneic) iPS cell derived-cardiomyocyte sheet
Human (allogeneic) iPS cell derived-cardiomyocyte sheet
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04696328 | Dec 2019 → May 2022 | myocardial ischemia | Osaka University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human (allogeneic) iPS cell derived-cardiomyocyte sheet | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04696328 ↗ |
| Modality | Cell therapy | “human (allogeneic) iPS cell-derived cardiomyocyte sheet transplantation” NCT04696328 ↗ |